Metropolitan Life Insurance Company (MetLife)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,153	Closed	-$77.9K	–	2854
2021 Q3	$77.9K	Hold	9,153	–	–	﹤0.01%	2652
2021 Q2	$150K	Buy	9,153 +1,195	+15%	+$24.1K	﹤0.01%	2362
2021 Q1	$176K	Hold	7,958	–	–	﹤0.01%	2113
2020 Q4	$246K	Hold	7,958	–	–	﹤0.01%	1801
2020 Q3	$162K	Buy	7,958 +2,288	+40%	+$40.2K	﹤0.01%	1916
2020 Q2	$87.1K	Buy	+5,670	New	+$65.4K	﹤0.01%	2339

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TCRR Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 9,153 shares — an estimated $77.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TCRR in Q2 2020 and held it in 6 quarters. The position peaked at $246K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 9,153 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $77.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Metropolitan Life Insurance Company (MetLife)'s TCR2 Therapeutics Inc. Common Stock position peaked at $246K in Q4 2020.
122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.